GlassScriptPhysician profile
Waqas Rehman
NPI 1750546610
$11,338.39
in general payments reported to CMS, 2019-2025
82 companies · $2,359 in 2025
The $2,359 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $570 · 2021: $2,337 · 2022: $829 · 2023: $1,765 · 2024: $2,805 · 2025: $2,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,170 · Long Term Medical Supply Or Device Loan: $1,696 · Education: $62.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,170.42 |
| Long Term Medical Supply Or Device Loan | $1,696.38 |
| Education | $62.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,155.14 | 2019-2025 | Tagrisso, Enhertu, Calquence |
| Novartis Pharmaceuticals Corporation | $2,141.46 | 2019-2025 | |
| Janssen Biotech, INC. | $609.40 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Genzyme Corporation | $406.58 | 2019-2025 | |
| Daiichi Sankyo INC. | $364.78 | 2019-2025 | Enhertu, Injectafer |
| Pfizer INC. | $313.14 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $281.82 | 2020-2025 | Opdivo, Opdualag, Krazati |
| Lilly USA, LLC | $243.16 | 2019-2025 | Verzenio, Jaypirca |
| Abbvie INC. | $235.69 | 2020-2025 | |
| Incyte Corporation | $213.95 | 2019-2024 | Monjuvi, Pemazyre |
| Stemline Therapeutics INC. | $213.20 | 2023-2025 | Orserdu |
| Gilead Sciences, INC. | $211.59 | 2019-2025 | Trodelvy |
| Eisai INC. | $186.46 | 2019-2025 | |
| Celgene Corporation | $175.66 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Glaxosmithkline, LLC. | $172.48 | 2020-2025 | Ojjaara, Jemperli, Zejula |
Show all 81 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $169.54 | 2022-2025 | Libtayo |
| Celltrion USA INC. | $168.69 | 2023-2024 | Vegzelma |
| Astellas Pharma US INC | $162.25 | 2019-2024 | Xtandi, Padcev, Vyloy |
| Janssen Pharmaceuticals, INC | $142.43 | 2019-2024 | Xarelto |
| Genentech USA, INC. | $136.05 | 2019-2024 | Lunsumio, Polivy, Gazyva |
| Beigene USA, INC. | $128.87 | 2023-2025 | Brukinsa, Tevimbra |
| Takeda Pharmaceuticals U.S.A., INC. | $119.61 | 2021-2025 | Glassia, Ninlaro, Alunbrig |
| Array Biopharma INC | $98.36 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Sobi, INC | $97.64 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.01 | 2020-2025 | |
| Servier Pharmaceuticals LLC | $88.42 | 2021-2024 | |
| Ipsen Biopharmaceuticals, INC | $84.71 | 2023-2025 | Onivyde, Somatuline Depot |
| Seagen INC. | $80.97 | 2019-2023 | Padcev |
| Coherus Oncology, INC. | $80.69 | 2020-2021 | |
| Exelixis INC. | $72.02 | 2022-2025 | Cabometyx |
| Morphosys, US INC. | $68.33 | 2021-2023 | Monjuvi |
| Taiho Oncology, INC. | $67.59 | 2022-2025 | |
| Springworks Therapeutics, INC. | $67.18 | 2024-2025 | Ogsiveo, Gomekli |
| Pharmacyclics LLC, An Abbvie Company | $65.81 | 2021-2023 | Imbruvica |
| Kyowa Kirin, INC. | $63.04 | 2019-2024 | Poteligeo |
| Adaptive Biotechnologies Corporation | $59.39 | 2024-2025 | Clonoseq |
| Ge Healthcare | $57.46 | 2022 | |
| Foundation Medicine, INC. | $57.45 | 2022-2023 | |
| Genmab U.S., INC. | $54.90 | 2023-2024 | Epkinly |
| Tempus Ai, INC | $52.99 | 2024 | Xt Cdx |
| Amgen INC. | $51.92 | 2022-2023 | Kyprolis, Blincyto, Lumakras |
| Kite Pharma, INC. | $51.43 | 2023 | Yescarta |
| Aveo Pharmaceuticals, INC. | $48.93 | 2023-2024 | Fotivda |
| Dendreon Pharmaceuticals LLC | $46.26 | 2023-2025 | Provenge |
| Alnylam Pharmaceuticals INC. | $45.63 | 2019-2025 | Onpattro, Givlaari |
| Fresenius Kabi USA, LLC | $42.89 | 2023-2024 | Stimufend |
| Epizyme, INC. | $37.30 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $35.97 | 2024-2025 | Xpovio |
| Janssen Scientific Affairs, LLC | $33.97 | 2019-2023 | |
| Rigel Pharmaceuticals, INC. | $33.61 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $31.80 | 2022-2023 | Empaveli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.78 | 2024-2025 | Gilotrif |
| Puma Biotechnology, INC. | $30.64 | 2021-2023 | |
| Sandoz INC. | $30.13 | 2024 | Zarxio |
| Octapharma USA, INC. | $30.09 | 2022-2025 | Octagam Immune Globulin (Human) |
| Blueprint Medicines Corporation | $30.00 | 2022-2024 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $29.56 | 2022-2025 | Ultomiris |
| Emd Serono, INC. | $29.38 | 2019-2023 | Bavencio |
| Secura Bio, INC. | $28.20 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $27.48 | 2023 | Orgovyx |
| Roche Diagnostics Corporation | $27.45 | 2019 | |
| Heron Therapeutics, INC. | $24.10 | 2023 | Sustol |
| Novocure INC. | $19.68 | 2025 | Optune Gio |
| Legend Biotech USA INC. | $19.25 | 2025 | Carvykti |
| Azurity Pharmaceuticals, INC. | $19.07 | 2025 | Vivimusta, Danziten |
| Invivyd INC | $18.69 | 2025 | Pemgarda |
| Agios Pharmaceuticals, INC. | $18.68 | 2023 | Pyrukynd |
| Fennec Pharmaceuticals, INC. | $18.65 | 2025 | Fyarro |
| Pharmacosmos Therapeutics INC. | $18.02 | 2023 | Monoferric |
| Beone Medicines USA, INC. | $17.22 | 2025 | Brukinsa |
| Csl Behring | $14.79 | 2025 | Privigen |
| Myovant Sciences INC. | $14.78 | 2021 | |
| Mirati Therapeutics, INC. | $14.73 | 2023 | Krazati |
| Amneal Pharmaceuticals LLC | $14.68 | 2025 | Alymsys |
| Tesaro, INC. | $14.45 | 2019 | |
| Iovance Biotherapeutics, INC. | $14.38 | 2025 | Amtagvi |
| Accord Healthcare, INC. | $14.24 | 2023 | |
| Clovis Oncology, INC. | $13.99 | 2019 | |
| Eusa Pharma (US) LLC | $13.55 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.55 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.56 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waqas Rehman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.